1. Formoterol reduces muscle wasting in mice undergoing doxorubicin chemotherapy
- Author
-
Edson Alves de Lima Junior, Alexandre Abilio de Souza Teixeira, Loreana Sanches Silveira, Queralt Jové, Natalia Álvarez Ladrón, Marcelo G. Pereira, Francisco Javier López-Soriano, Josep M. Argilés, Patrícia Chakur Brum, Silvia Busquets, and José Cesar Rosa Neto
- Subjects
beta2-adrenergic agonist ,doxorubicin ,chemotherapy ,Lewis lung carcinoma ,muscle wasting ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundEven though doxorubicin (DOX) chemotherapy promotes intense muscle wasting, this drug is still widely used in clinical practice due to its remarkable efficiency in managing cancer. On the other hand, intense muscle loss during the oncological treatment is considered a bad prognosis for the disease’s evolution and the patient’s quality of life. In this sense, strategies that can counteract the muscle wasting induced by DOX are essential. In this study, we evaluated the effectiveness of formoterol (FOR), a β2-adrenoceptor agonist, in managing muscle wasting caused by DOX.Methods and resultsTo evaluate the effect of FOR on DOX-induced muscle wasting, mice were treated with DOX (2.5 mg/kg b.w., i.p. administration, twice a week), associated or not to FOR treatment (1 mg/kg b.w., s.c. administration, daily). Control mice received vehicle solution. A combination of FOR treatment with DOX protected against the loss of body weight (p
- Published
- 2024
- Full Text
- View/download PDF